PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Genetic variation increases risk of kidney disease progression in African-Americans

2013-11-09
(Press-News.org) Contact information: Bill Seiler
bseiler@umm.edu
410-328-8919
University of Maryland Medical Center
Genetic variation increases risk of kidney disease progression in African-Americans

Baltimore, MD – November 9, 2013 – New research provides direct evidence that genetic variations in some African Americans with chronic kidney disease contribute to a more rapid decline in kidney function compared with white Americans. The research, led by investigators from the University of Maryland School of Medicine and Johns Hopkins University, may help explain, in part, why even after accounting for differences in socioeconomic background, end-stage kidney disease is twice as prevalent among blacks as whites. Results are published online today in the New England Journal of Medicine.

“What we found is pretty remarkable — that variations in a single gene account for a large part of the racial disparity in kidney disease progression and risk for end-stage kidney disease,” says co-lead author and nephrologist Afshin Parsa, M.D., M.P.H., assistant professor of medicine and member of the Program in Personalized and Genomic Medicine at the University of Maryland School of Medicine. “If it were possible to reduce the effect of this gene, there could be a very meaningful decrease in progressive kidney and end-stage kidney disease within blacks.”

Previous landmark discoveries revealed that two common variants within a gene called apolipoprotein L1 (APOL1) were strongly associated with non-diabetic end-stage renal disease in blacks. Having only one copy of the variant APOL1 gene variant is associated with a health benefit – protection against African sleeping sickness, a potentially lethal parasitic infection transmitted by the tsetse fly, found only in sub-Saharan Africa. However, people with two copies of the variant are at a higher risk for kidney disease.

The current research expands on these prior findings and demonstrates the effect of these variants on the progression of established kidney disease and development of end-stage renal disease; analyzes their role in black-versus-white renal disease disparities; investigates their effect in patients with diabetes and observes the impact of blood pressure control on APOL1-associated disease progression.

According to Dr. Parsa, approximately 13 percent of the African American population has two copies of the risk variants. Fortunately, most of those at risk do not develop kidney disease. The researchers analyzed the role of APOL1 gene variants in two longitudinal studies of patients with kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) and the African American Study of Kidney Disease and Hypertension (AASK), both sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). Dr. Parsa examined the CRIC study data, while co-lead author and Johns Hopkins epidemiologist W.H. Linda Kao, Ph.D., M.H.S., analyzed the AASK data.

The ASSK study consisted of nearly 700 non-diabetic African American participants whose kidney disease was attributed to hypertension, a leading cause of kidney failure. The study was initially a clinical trial that tested the effects of different classes of anti-hypertensive medication and two different blood pressure goals on the progression of kidney disease.

“The hypertension intervention had similar effects in persons with and without the high-risk APOL1 variant, suggesting that patients in the APOL1 high risk group still benefit from these drugs,” says Dr. Kao. “Blacks with two copies of the high-risk APOL1 variants were at higher risk for kidney disease progression, but it is important to note that kidney disease in about 40 percent of blacks in the AASK study who also carried the high-risk variants had not progressed at the time of the study. This finding raises the importance of identifying factors that may modify the effect of the APOL1 risk variants.”

CRIC expanded on AASK, increasing the number of patients to include those with diabetes, one of the most common causes of kidney failure in the United States. CRIC followed 3,000 white and black patients with renal disease; 46 percent of the participants had diabetes and 48 percent of the participants were of African descent. CRIC compared whites with blacks, with and without the APOL1 risk variants, in diabetics and non-diabetics.

“In CRIC,” says Dr. Parsa, “we found that, indeed, the gene variants account for a very significant portion of the faster progression in blacks versus whites. If a person had two copies of the APOL1 risk variant, their kidney disease worsened faster and their chance of developing end-stage kidney disease nearly doubled.” The researchers also found that APOL1 variants equally affected progression rates in patients with diabetes, a finding that had not been fully realized in previous studies. “These results suggest that APOL1 gene variants affect the progression of established renal disease, regardless of the primary cause,” adds Dr. Parsa.

Beyond that, however, the analysis showed that black patients without the APOL1 high-risk variants still had a slightly increased chance for end-stage renal disease. For this reason, the researchers conclude there may be some remaining unaccounted factors contributing to increased progression of kidney disease in blacks.

Further research will focus on the specific activity of the APOL1 variants. “These gene variants can modify the gene’s function. However, we have not yet been able to delineate how they affect renal disease progression. Our next line of research is to find out what pathways are triggered by these gene variants and how they could cause worsening of renal disease,” says Dr. Parsa.

“This study underscores the importance of research examining genetic and racial disparities as part of the effort to improve outcomes by personalizing medicine,” says E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the University of Maryland School of Medicine. “It may lead to targeted treatments tailored to the individual’s genetic makeup and could significantly reduce the toll of kidney disease.”

An estimated 20 million or more American adults have chronic kidney disease, and over 400,000 people in the United States and 2 million worldwide depend on dialysis to treat kidney failure.

INFORMATION:

About the University of Maryland School of Medicine

Established in 1807, the University of Maryland School of Medicine is the first public medical school in the United States, the first to institute a residency-training program. The School of Medicine was the founding school of the University of Maryland and today is an integral part of the 11-campus University System of Maryland. On the University of Maryland's Baltimore campus, the School of Medicine serves as the anchor for a large academic health center which aims to provide the best medical education, conduct the most innovative biomedical research and provide the best patient care and community service to Maryland and beyond. http://www.medschool.umaryland.edu

Parsa A, Kao WHL, et al. "APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease." N ENGL J MED. November 9, 2013, at NEJM.org. DOI: 10.1056/NEJMoa1310345

END



ELSE PRESS RELEASES FROM THIS DATE:

Gene puts African-Americans at higher risk for kidney failure

2013-11-09
Gene puts African-Americans at higher risk for kidney failure Genetic factors in African Americans with chronic kidney disease (CKD) put them at a greater risk for end-stage renal disease (ESRD) compared to white Americans, according ...

Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis

2013-11-09
Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis ATLANTA, GA – Doctors at the North Shore-LIJ Health System on Saturday will present late-breaking data showing that an investigational drug Triferic ...

Kidney Week 2013: New innovations in clinical science

2013-11-09
Kidney Week 2013: New innovations in clinical science Atlanta, GA (November 9, 2013)—A variety of recent studies highlight new and innovative research efforts that could help improve individuals' kidney health. Below are the findings of some of these studies, ...

Kidney Week 2013: New clinical trials reveal insights on treating patients with kidney disease

2013-11-09
Kidney Week 2013: New clinical trials reveal insights on treating patients with kidney disease Atlanta, GA (November 9, 2013)—Recently completed clinical trials highlight the potential of new therapies for individuals with kidney disease. Below are the ...

Kidney damage in first responders linked to 9/11

2013-11-09
Kidney damage in first responders linked to 9/11 New research findings of WTC-CHEST Program at Icahn School of Medicine at Mount Sinai presented at the 2013 American Society of Nephrology Meeting during National Kidney Week For ...

Use of calcium-channel blocker and antibiotic associated with small increased risk of kidney injury

2013-11-09
Use of calcium-channel blocker and antibiotic associated with small increased risk of kidney injury Among older adults taking a calcium-channel blocker, simultaneous use of the antibiotic clarithromycin, compared with azithromycin, was associated ...

Gene hastens kidney disease progression in African-Americans

2013-11-09
Gene hastens kidney disease progression in African-Americans A gene variant common in African-Americans predicts that people with that gene who also have chronic kidney disease (CKD) are twice as likely to progress ...

Repurposed drug may be first targeted treatment for serious kidney disease

2013-11-09
Repurposed drug may be first targeted treatment for serious kidney disease Treatment with rheumatoid arthritis drug saved transplanted kidney in four patients, achieved remission in a fifth A drug approved for the treatment of rheumatoid arthritis may ...

Universals of conversation

2013-11-09
Universals of conversation Max Planck researchers found that words that signal problems with understanding are similar across languages A word like 'Huh?' —used when one has not caught what someone just said—appears to be universal: it is found to have very ...

High-energy physicists predict new family of four-quark objects

2013-11-09
High-energy physicists predict new family of four-quark objects New charged charmonium-like states observed at BESIII An international team of high-energy physicists says the discovery of an electrically charged subatomic particle called Zc(4020) is ...

LAST 30 PRESS RELEASES:

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

Mission accomplished for the “T2T” Hong Kong Bauhinia Genome Project

[Press-News.org] Genetic variation increases risk of kidney disease progression in African-Americans